Skip to content

News

Press Releases

Q32 Bio Presents Preclinical Data Supporting Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021

Data demonstrate ADX-097’s ability to precisely target complement blockade to diseased tissue In multiple renal disease models, ADX-097 potently inhibits disease-causing complement activation while avoiding systemic complement inhibition Cambridge, Mass. – November 8, 2021 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced preclinical data from the Company’s lead […]

Q32 Bio to Present Preclinical Data on Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021

Cambridge, Mass. – October 18, 2021 – Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that it will present preclinical data supporting the Company’s lead program for innate immunity, ADX-097, during an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2021, taking place virtually from November 4 […]

Q32 Bio Announces Appointment of Kathy LaPorte to its Board of Directors

Cambridge, Mass. – August 3, 2021 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Kathy LaPorte to its Board of Directors. Ms. LaPorte, who brings over 30 years of experience in executive leadership and venture investing within the biotech industry, will serve as the Chair […]

Q32 Bio Appoints Adam Cutler as Chief Financial Officer

Cambridge, Mass. – July 7, 2021 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Adam Cutler as Chief Financial Officer. Mr. Cutler will be responsible for all aspects of Q32’s financial strategy and operations.

Q32 Bio to Present at the Jefferies Virtual Healthcare Conference

Cambridge, Mass. – May 27, 2021 /PRNewswire/ — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that Michael Broxson, Chief Executive Officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:30 pm ET.

Q32 Bio Appoints Dr. Jason Campagna as Chief Medical Officer

Cambridge, Mass. (March 9, 2021) – Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of Jason Campagna, M.D., Ph.D. as Chief Medical Officer. Dr. Campagna brings more than 15 years of biotech and pharmaceutical experience to the Q32 Bio executive team during a critical growth and development period for the company.